Oct
2026
Fiera Milano, Italy
Visit us
stand 6K67, Contract Manufacturing & Services

Tianjin Pharmacn Medical Technology Co., Ltd.

Exhibitor at CPHI Milan 2026
About Us

Tianjin Pharmacn Medical Technology Co., Ltd is a high-tech enterprise, integrating the R&D, manufacturing and marketing of active pharmaceutical ingredients (APIs) and intermediates. It has R&D center,optimization and industrial preparation pilot workshops. Focusing on the R & D and manufacturing of advanced pharmaceutical raw materials and intermediates, especially in the field of anti-tumor, diabetes and cardiovascular intermediates. At the same time, the company can also provide impurity tracking, stability analysis and CTD documentation and other technical services. ...

Read more Show less
Products
Show more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    China
  • On CPHI since:
    2015
  • Certificates:
    2
  • Employees:
    250 - 499
Company types
Biopharmaceutical company
Manufacturer/Innovator
Pharmaceutical company
Primary activities
API Producer
Intermediates Manufacturer
View company profile
Contact info
  • +8617822028513
  • 6 Haitaifazhan Sixth Rd,Huayuan Industrial Area, 300384, Tianjin, China
Show contact info Hide contact info
Event information
CPHI Milan 2026
  • 6 Oct 2026 - 8 Oct 2026
  • Fiera Milano, Italy
  • Visit us at stand 6K67, Contract Manufacturing & Services

Products Featured at CPHI Milan 2026

  • Palbociclib Series

    Product Palbociclib Series

    Palbociclib is a Kinase Inhibitor. The mechanism of action of palbociclib is as a Kinase Inhibitor, and Cytochrome P450 3A Inhibitor.
  • Ribociclib Series

    Product Ribociclib Series

    a cyclin-dependent kinase (CDK) inhibitor that targets cyclin D1/CDK4 and cyclin D3/CDK6 at nanomolar concentrations. It inhibits retinoblastoma protein phosphorylation, which prevents CDK-mediated G1-S phase transition, arresting the cell cycle in the G1 phase, suppressing DNA synthesis, and inhibiti...
  • Cabozantinib Series

    Product Cabozantinib Series

    Cabozantinib was approved in November 2012 for the treatment of patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). Cabozantinib was granted orphan drug status by the FDA to facilitate development of newtreatment options for patients with MTC. It is a me...
  • Iguratimod Series

    Product Iguratimod Series

    Iguratimod is a disease modifying anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). Preclinical in vivo studies indicated that iguratimod was effective in an established adjuvant-induced arthritis model (ED40=3.6 mg/kg) in rats and also efficacious in a type II collagen-induced ar...
  • Dexmedetomidine hydrochloride Series

    Product Dexmedetomidine hydrochloride Series

    Dexmedetomidine was launched in the US as an i.v. infusion for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care unit, This imidazole derivative is the (S)-enantiomer of medetomidine that can be obtained via fractional crystallization of the tartrate...

Tianjin Pharmacn Medical Technology Co., Ltd. Resources (1)